Latest Financial Results

Q3 2022
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2021
Report Links
Email Alerts
Sign up today and receive company updates straight to your inbox.
Company Overview
CohBar (NASDAQ: CWBR) is a clinical-stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. CohBar has assembled the leading position in exploring the mitochondrial genome and its utility for the development of novel therapeutics, including world-renowned expertise in mitochondrial biology, a broad intellectual property estate, key opinion leaders and disciplined drug discovery and development processes. CohBar is utilizing its Mito+ platform to develop modified versions of natural peptides called analogs to treat a variety of serious conditions, with a focus on diseases involving inflammation and fibrosis. The company’s most advanced compound, CB4211, which is under development for the treatment of NASH and obesity, completed a successful Phase 1a/1b clinical trial in August 2021.
IR Contacts
Headquarters
CohBar, Inc.
1455 Adams Drive
Suite 2050
Menlo Park, CA 94025
T: (650) 446-7888
info@cohbar.com
Investor Relations
Jordyn Tarazi
Director, Investor Relations
T: (650) 445-4441
jordyn.tarazi@cohbar.com
Transfer Agent
TSX Trust Company
301 – 100 Adelaide St W
Toronto, ON M5H 4H1